Information Provided By: 
Fly News Breaks for December 3, 2018
DGX
Dec 3, 2018 | 07:18 EDT
SunTrust analyst David MacDonald lowered his price target on Quest Diagnostics to $96 and kept his Hold rating after its analyst day. MacDonald notes that the presentation indicated that the headwinds around reimbursements will accelerate in 2019, adding that the trends around organic volume and patient concessions also "bear watching". Longer term, the analyst remains positive on Quest Diagnostics' fundamentals, stating that the "expanded health plan access" is also a meaningful opportunity for the company.
News For DGX From the Last 2 Days
DGX
Apr 25, 2024 | 05:10 EDT
DGX
Apr 24, 2024 | 09:46 EDT
DGX
Apr 24, 2024 | 09:10 EDT
DGX
Apr 24, 2024 | 06:55 EDT
UBS raised the firm's price target on Quest Diagnostics to $146 from $139 and keeps a Neutral rating on the shares. UBS is more confident that Quest can hit its margin expansion story following the Q2 print and the firm's call with management, the analyst tells investors in a research note. Labor cost trends seem to have already peaked and Covid revenues should no longer be a headwind starting 2H, while above market base volume growth continues, the firm notes.
DGX
Apr 24, 2024 | 06:43 EDT
DGX
Apr 24, 2024 | 06:24 EDT
Citi raised the firm's price target on Quest Diagnostics to $145 from $135 and keeps a Neutral rating on the shares post the Q1 report. The company increased the midpoint of its fiscal 2024 revenue target and management anticipates the rest of fiscal year to follow regular seasonality on a revenue and margin basis with a step-up into Q2, the analyst tells investors in a research note.
